| pubmed-article:16978720 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16978720 | lifeskim:mentions | umls-concept:C0220650 | lld:lifeskim |
| pubmed-article:16978720 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16978720 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:16978720 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16978720 | lifeskim:mentions | umls-concept:C1273404 | lld:lifeskim |
| pubmed-article:16978720 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16978720 | pubmed:dateCreated | 2006-10-18 | lld:pubmed |
| pubmed-article:16978720 | pubmed:abstractText | To prospectively evaluate efficacy and side effects of hypofractionated stereotactic radiotherapy (hfSRT) for irresectable brain metastases not amenable to radiosurgery (SRS). | lld:pubmed |
| pubmed-article:16978720 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16978720 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978720 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16978720 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16978720 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16978720 | pubmed:issn | 0167-8140 | lld:pubmed |
| pubmed-article:16978720 | pubmed:author | pubmed-author:SauerRolfR | lld:pubmed |
| pubmed-article:16978720 | pubmed:author | pubmed-author:GrabenbauerGe... | lld:pubmed |
| pubmed-article:16978720 | pubmed:author | pubmed-author:GanslandtOliv... | lld:pubmed |
| pubmed-article:16978720 | pubmed:author | pubmed-author:LambrechtUlri... | lld:pubmed |
| pubmed-article:16978720 | pubmed:author | pubmed-author:Ernst-Stecken... | lld:pubmed |
| pubmed-article:16978720 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16978720 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:16978720 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16978720 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16978720 | pubmed:pagination | 18-24 | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:meshHeading | pubmed-meshheading:16978720... | lld:pubmed |
| pubmed-article:16978720 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16978720 | pubmed:articleTitle | Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. | lld:pubmed |
| pubmed-article:16978720 | pubmed:affiliation | Department of Radiation Therapy and Novalis Shaped Beam Surgery Center, University of Erlangen, Germany. antje.ernst-stecken@strahlen.imed.uni-erlangen.de | lld:pubmed |
| pubmed-article:16978720 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16978720 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
